Cargando…
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
Autores principales: | Houot, Roch, Bachy, Emmanuel, Cartron, Guillaume, Gros, François-Xavier, Morschhauser, Franck, Oberic, Lucie, Gastinne, Thomas, Feugier, Pierre, Duléry, Rémy, Thieblemont, Catherine, Joris, Magalie, Jardin, Fabrice, Choquet, Sylvain, Casasnovas, Olivier, Brisou, Gabriel, Cheminant, Morgane, Bay, Jacques-Olivier, Gutierrez, Francisco Llamas, Menard, Cédric, Tarte, Karin, Delfau, Marie-Hélène, Portugues, Cédric, Itti, Emmanuel, Palard-Novello, Xavier, Blanc-Durand, Paul, Al Tabaa, Yassine, Bailly, Clément, Laurent, Camille, Lemonnier, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579050/ https://www.ncbi.nlm.nih.gov/pubmed/37814064 http://dx.doi.org/10.1038/s41591-023-02624-w |
Ejemplares similares
-
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial
por: Houot, Roch, et al.
Publicado: (2023) -
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY
por: Houot, Roch, et al.
Publicado: (2023) -
P1123: EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA: RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY
por: Delfau-Larue, Marie-Helene, et al.
Publicado: (2023) -
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022) -
Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021)